A new method to treat heart muscle thickening in patients who can't have surgery
Official title: A Controlled Septal Ablation for Inoperable Hypertrophic Cardiomyopathy
Funded at University of Texas Arlington · NIH-10514872 · Data updated 2026-11-12
This study is exploring a new, safer way to treat hypertrophic cardiomyopathy (HCM) by using a gentle technique to help reduce the thickened heart muscle, so patients can feel better without needing major surgery.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Arlington NIH-funded |
| Lab location | 1 site (Arlington, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $433,120 |
| NIH project number | 1R15HL159599-01A1 |
| Project ID | NIH-10514872 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with hypertrophic cardiomyopathy who have not responded adequately to medication and are considered poor candidates for surgical intervention.
✕Less likely to help
Patients with mild hypertrophic cardiomyopathy or those who are suitable for traditional surgical options may not benefit from this research.
What this research studies
This research investigates a novel approach to treat hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, causing obstruction in blood flow. The current treatment, alcohol septal ablation, can lead to serious complications due to the uncontrolled nature of alcohol diffusion. This project aims to develop a safer and more effective ablation system that minimizes risks while effectively targeting the thickened heart muscle. Patients will be treated using a minimally invasive technique that could provide relief from symptoms without the need for open-heart surgery.
Why it matters
Potential benefit: If successful, this research could provide a safer treatment option for patients with hypertrophic cardiomyopathy who are not candidates for traditional surgery.
How similar studies have gone: While alcohol septal ablation has been widely used, this research aims to innovate beyond existing methods, making it a novel approach in the field.
Where this research is happening
-
University of Texas Arlington
Arlington, United States Active
Researchers
- Principal investigator: Liao, Jun — University of Texas Arlington
- Study coordinator: Liao, Jun
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.